<p>Savara Inc.（纳斯达克代码：SVRA - 免费报告）- HC Wainwright 的投资分析师在 12 月 23 日（星期二）发布的研究报告中上调了 Savara 2027 财年的每股收益（EPS）预期。HC Wainwright 的分析师 A. Fein 现在预测该公司在该年度的每股收益为（$0.16），高于之前预测的（$0.18）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $10.00。Savara 当前全年的共识收益预期为每股（$0.45）。HC Wainwright 还对 Savara 2028 财年的收益预期为每股 $0.13。</p>
<p>其他分析师最近也发布了关于该股票的报告。瑞银集团在星期二的研究报告中将 Savara 的目标价设定为 $10.00。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Savara 的 “卖出（d-）” 评级。Oppenheimer 在星期二的研究报告中将 Savara 的目标价设定为 $10.00。JMP Securities 在 10 月 23 日（星期四）的报告中将 Savara 的目标价从 $8.00 上调至 $11.00，并给予该股票 “市场表现优于大盘” 的评级。最后，富国银行在 12 月 18 日（星期四）的报告中将 Savara 的目标价从 $7.00 上调至 $9.00，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Savara 目前的平均评级为 “适度买入”，共识目标价为 $9.13。</p>
<p><strong>阅读我们关于 Savara 的最新股票报告</strong></p>
<h2>Savara 股票表现</h2>
<p>Savara 股票在星期四开盘价为 $6.40。Savara 的 52 周低点为 $1.89，52 周高点为 $7.01。该公司的速动比率为 7.65，流动比率为 7.65，债务与股本比率为 0.32。该公司的 50 日移动平均线为 $5.12，200 日移动平均线为 $3.66。该公司的市值为 13 亿美元，市盈率为 -12.07，贝塔值为 0.23。</p>
<p>Savara（纳斯达克代码：SVRA - 获取免费报告）最近在 11 月 12 日（星期三）发布了其财报。该公司报告的季度每股收益为（$0.14），低于分析师的共识预期（$0.13）$0.01。</p>
<h2>机构投资者对 Savara 的看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 SVRA 的持股。保诚金融公司在第二季度购买了 Savara 的新股份，价值约 $30,000。法国巴黎银行金融市场在第二季度将其在 Savara 的持股增加了 52.3%。法国巴黎银行金融市场目前拥有 13,473 股该公司的股票，价值 $31,000，此前在该期间内又购买了 4,626 股。May Hill Capital LLC 在第二季度购买了 Savara 的新股份，价值 $32,000。Brevan Howard Capital Management LP 在第二季度购买了 Savara 的新股份，价值 $33,000。最后，拉塞尔投资集团在第三季度将其在 Savara 的持股增加了 930.5%。拉塞尔投资集团目前拥有 10,480 股该公司的股票，价值 $37,000，此前在该期间内又购买了 9,463 股。目前，87.93% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Savara</h2>
<p>（获取免费报告）</p>
<p>Savara Inc（纳斯达克代码：SVRA）是一家临床阶段的生物制药公司，专注于开发和商业化针对罕见呼吸疾病的疗法。该公司专注于引进、推进并可能将新疗法推向市场，以应对具有高度未满足医疗需求的严重肺部疾病。</p>
<p>该公司的主要候选药物 Molgradex（重组人粒细胞 - 巨噬细胞集落刺激因子，或 GM-CSF）正在接受监管审查，用于治疗自身免疫性肺泡蛋白沉积症（PAP），这是一种以表面活性剂积累为特征的罕见肺病。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Savara 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Savara 吗？</h2>
<p>在你考虑 Savara 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Savara 并不在名单上。</p>
<p>虽然 Savara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

SVRA

<p>HC Wainwright 将 Savara Inc. 的 2027 财年每股收益（EPS）预估从（$0.18）上调至（$0.16）。该公司维持 “买入” 评级，目标价为 $10.00。其他分析师的评级则各有不同，平均目标价为 $9.13。Savara 的股票开盘价为 $6.40，52 周价格区间为 $1.89 至 $7.01。该公司专注于罕见呼吸疾病的治疗，其主要候选药物正在接受监管审查</p>

<p>Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday, December 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.18). HC Wainwright has a &#34;Buy&#34; rating and a $10.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2028 earnings at $0.13 EPS.</p>
<div class="lb-trans"><p>Savara Inc.（纳斯达克代码：SVRA - 免费报告）- HC Wainwright 的投资分析师在 12 月 23 日（星期二）发布的研究报告中上调了 Savara 2027 财年的每股收益（EPS）预期。HC Wainwright 的分析师 A. Fein 现在预测该公司在该年度的每股收益为（$0.16），高于之前预测的（$0.18）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $10.00。Savara 当前全年的共识收益预期为每股（$0.45）。HC Wainwright 还对 Savara 2028 财年的收益预期为每股 $0.13。</p>
</div><p>Other analysts have also recently issued reports about the stock. UBS Group set a $10.00 target price on shares of Savara in a research report on Tuesday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Savara in a research note on Wednesday, October 8th. Oppenheimer set a $10.00 price objective on Savara in a research report on Tuesday. JMP Securities lifted their target price on Savara from $8.00 to $11.00 and gave the stock a &#34;market outperform&#34; rating in a report on Thursday, October 23rd. Finally, Wells Fargo &amp; Company increased their price target on Savara from $7.00 to $9.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Savara presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.13.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该股票的报告。瑞银集团在星期二的研究报告中将 Savara 的目标价设定为 $10.00。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Savara 的 “卖出（d-）” 评级。Oppenheimer 在星期二的研究报告中将 Savara 的目标价设定为 $10.00。JMP Securities 在 10 月 23 日（星期四）的报告中将 Savara 的目标价从 $8.00 上调至 $11.00，并给予该股票 “市场表现优于大盘” 的评级。最后，富国银行在 12 月 18 日（星期四）的报告中将 Savara 的目标价从 $7.00 上调至 $9.00，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Savara 目前的平均评级为 “适度买入”，共识目标价为 $9.13。</p>
</div><p><strong>Read Our Latest Stock Report on Savara</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Savara 的最新股票报告</strong></p>
</div><h2>Savara Price Performance</h2>
<div class="lb-trans"><h2>Savara 股票表现</h2>
</div><p>Savara stock opened at $6.40 on Thursday. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm's fifty day moving average is $5.12 and its 200 day moving average is $3.66. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -12.07 and a beta of 0.23.</p>
<div class="lb-trans"><p>Savara 股票在星期四开盘价为 $6.40。Savara 的 52 周低点为 $1.89，52 周高点为 $7.01。该公司的速动比率为 7.65，流动比率为 7.65，债务与股本比率为 0.32。该公司的 50 日移动平均线为 $5.12，200 日移动平均线为 $3.66。该公司的市值为 13 亿美元，市盈率为 -12.07，贝塔值为 0.23。</p>
</div><p>Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01).</p>
<div class="lb-trans"><p>Savara（纳斯达克代码：SVRA - 获取免费报告）最近在 11 月 12 日（星期三）发布了其财报。该公司报告的季度每股收益为（$0.14），低于分析师的共识预期（$0.13）$0.01。</p>
</div><h2>Institutional Investors Weigh In On Savara</h2>
<div class="lb-trans"><h2>机构投资者对 Savara 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Prudential Financial Inc. bought a new stake in shares of Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares during the period. May Hill Capital LLC bought a new stake in shares of Savara during the second quarter worth $32,000. Brevan Howard Capital Management LP bought a new stake in shares of Savara during the second quarter worth $33,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after purchasing an additional 9,463 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 SVRA 的持股。保诚金融公司在第二季度购买了 Savara 的新股份，价值约 $30,000。法国巴黎银行金融市场在第二季度将其在 Savara 的持股增加了 52.3%。法国巴黎银行金融市场目前拥有 13,473 股该公司的股票，价值 $31,000，此前在该期间内又购买了 4,626 股。May Hill Capital LLC 在第二季度购买了 Savara 的新股份，价值 $32,000。Brevan Howard Capital Management LP 在第二季度购买了 Savara 的新股份，价值 $33,000。最后，拉塞尔投资集团在第三季度将其在 Savara 的持股增加了 930.5%。拉塞尔投资集团目前拥有 10,480 股该公司的股票，价值 $37,000，此前在该期间内又购买了 9,463 股。目前，87.93% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Savara</h2>
<div class="lb-trans"><h2>关于 Savara</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.</p>
<div class="lb-trans"><p>Savara Inc（纳斯达克代码：SVRA）是一家临床阶段的生物制药公司，专注于开发和商业化针对罕见呼吸疾病的疗法。该公司专注于引进、推进并可能将新疗法推向市场，以应对具有高度未满足医疗需求的严重肺部疾病。</p>
</div><p>The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.</p>
<div class="lb-trans"><p>该公司的主要候选药物 Molgradex（重组人粒细胞 - 巨噬细胞集落刺激因子，或 GM-CSF）正在接受监管审查，用于治疗自身免疫性肺泡蛋白沉积症（PAP），这是一种以表面活性剂积累为特征的罕见肺病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Savara</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Savara 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SVRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Savara Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Savara 吗？</h2>
</div><p>Before you consider Savara, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Savara 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Savara 并不在名单上。</p>
</div><p>While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Savara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 对 Savara 2027 财年收益的预测是什么？